Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Transformed Non-Hodgkin Lymphoma"
Page 1
A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Front Immunol. 2023 Apr 27;14:1178403. doi: 10.3389/fimmu.2023.1178403. eCollection 2023.
Front Immunol. 2023.
PMID: 37180149
Free PMC article.
We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to March 3rd 2022 for full-length articles and conference abstracts of clinical trials employing CD22-targeting CAR T-cells in acute lymphocytic leukemia (ALL) and …
We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to March 3rd 2022 for ful …
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, Muffly L.
Grover P, et al.
Blood Adv. 2022 Mar 8;6(5):1608-1618. doi: 10.1182/bloodadvances.2020003482.
Blood Adv. 2022.
PMID: 34610109
Free PMC article.
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in children and younger adults. ...
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for relapsed/refractory (r/r) B-cell acute lymph …
Item in Clipboard
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K.
Proudman D, et al.
Adv Ther. 2022 Apr;39(4):1678-1696. doi: 10.1007/s12325-022-02054-z. Epub 2022 Feb 14.
Adv Ther. 2022.
PMID: 35157216
Free PMC article.
INTRODUCTION: Tazemetostat is an enhancer of zeste homolog 2 (EZH2) inhibitor recommended for patients with relapsed/refractory (R/R) follicular lymphoma (FL) after demonstrating single-agent, antitumor activity in patients with wild-type or mutant EZH2. ...Only the tazeme …
INTRODUCTION: Tazemetostat is an enhancer of zeste homolog 2 (EZH2) inhibitor recommended for patients with relapsed/refractory (R/R) follic …
Item in Clipboard
Cite
Cite